Pharma Journalist -

Adaptimmune Therapeutics embarks on manufacturing T-cell therapy to treat  cancer entitled SPEAR T-cells for a patient at its Navy Yard facility in Philadelphia. In addition to this…
Read More...

Celgene Corporation and Impact Biomedicinessigned and agreement that entails acquisition of Impact Biomedicines enabling development of fedratinib  for myelofibrosis and polycythemia…
Read More...

Following the league of leading in the markets of  clinical research organizations, Optimapharm obtained Czech CRO company MKS research. Following the acquisition , Optimapharm will…
Read More...

Ipsen declared the appointment of Richard Paulson as Executive Vice-president and Chief Executive Officer of Ipsen North America accountable for  commercial operations throughout the…
Read More...

Concert Pharmaceuticals asserted that the U.S FDA has offered Fast Track designation for CTP-543, inhibitor for treatment of moderate-to severe Alopecia Areata discerned as a serious…
Read More...

Fresenius Kabi confirmed the availability of Bortezomib for injection  in the United States. Fresenius Kabi Bortezomib for Injection is available as a single dose vial containing 3.5 mg…
Read More...

GSK asserted that it has received approval from the US FDA center for biologics Evaluation and Research thereby hinting at the usage of FLUARIX QUADRIVALENT in persons 6 months and…
Read More...

FDA approved use of Lynparza (olaparib tablets) to include treatment of patients with certain types of  Breast Cancer that have become widespread and whose tumors possess inherited…
Read More...

Gobal open-access biologics technology platform company, Wuxi Biologics declares that Dr. Chiang Syin has been appointed by Wuxi Biologics as its Chief Quality Officer accountable for…
Read More...

Boston Scientific Corporation declared optimistic outcomes from the WHISPER randomized controlled Trial.According to the data presented at the 2018 Annual meeting of the North American …
Read More...